Concord Biotech 대차 대조표 상태
재무 상태 기준 확인 5/6
Concord Biotech has a total shareholder equity of ₹15.3B and total debt of ₹97.4M, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are ₹17.0B and ₹1.7B respectively. Concord Biotech's EBIT is ₹4.0B making its interest coverage ratio -395.1. It has cash and short-term investments of ₹2.8B.
주요 정보
0.6%
부채 비율
₹97.38m
부채
| 이자 보상 비율 | -395.1x |
| 현금 | ₹2.82b |
| 주식 | ₹15.27b |
| 총 부채 | ₹1.74b |
| 총 자산 | ₹17.01b |
최근 재무 상태 업데이트
재무 상태 분석
단기부채: CONCORDBIO's short term assets (₹9.0B) exceed its short term liabilities (₹1.4B).
장기 부채: CONCORDBIO's short term assets (₹9.0B) exceed its long term liabilities (₹319.1M).
부채 대 자본 내역 및 분석
부채 수준: CONCORDBIO has more cash than its total debt.
부채 감소: Insufficient data to determine if CONCORDBIO's debt to equity ratio has reduced over the past 5 years.
부채 범위: CONCORDBIO's debt is well covered by operating cash flow (2726.2%).
이자 보장: CONCORDBIO earns more interest than it pays, so coverage of interest payments is not a concern.